Inducible T cell co-stimulator (ICOS; CD278) is an activating receptor expressed on the surface of activated cytotoxic T cells, regulatory T cells (Tregs), NK cells and other types of T cells, having a distinct and opposing function than CTLA-4. The ligand ICOSL (B7-H2; CD275) is expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. ICOS/ICOSL signalling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. Recently, it has been shown that ICOS expression could be a useful predictive biomarker of response to checkpoint inhibitor treatments (e.g through the CTLA-4 axis).
LIT: ICOS Co-Stimulation: Friend or Foe? D.J. Wikenheiser & J.S. Stumhofer; Front. Immunol. 7, 304 (2016) • Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy: F. Amatore, et al.; Expert Opin. Ther. Targets 22, 343 (2018)
ICOSL (B7-H2/CD275) (human) ELISA Kit – Biomarker for Autoimmune Diseases & Cancers
The ICOSL (B7-H2/CD275) (human) ELISA Kit (Prod. No. AG-45B-0017) is a sandwich ELISA for specific quantitative determination of soluble human ICOSL [B7-H2/CD275] in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (55pg/ml).
Biologically Active ICOS and ICOSL Proteins
See Biologically Active ICOS and ICOSL Proteins here
VALIDATED Antibodies for ICOS and ICOSL Research
See VALIDATED Antibodies for ICOS and ICOSL Research here
Originally posted on adipogen.com/icos-icosl-pathway/
Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.